Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
Corvus Pharmaceuticals, Inc. will host a conference call and webcast on August 8, 2023, at 4:30 pm ET to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) or via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
08/01/2023 - 08:30 AM
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
BURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results.
The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib (CPI-818), an investigational, oral, small molecule drug that selectively inhibits ITK and is in a mid-stage clinical trial for patients with T cell lymphoma. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com .
INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522llea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750sseapy@realchemistry.com
When will Corvus Pharmaceuticals host a conference call and webcast?
Corvus Pharmaceuticals will host a conference call and webcast on August 8, 2023.
What will be discussed during the conference call and webcast?
The conference call and webcast will provide a business update and report second quarter 2023 financial results.
How can I access the conference call?
The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) or via the investor relations section of the Corvus website.
How long will the webcast replay be available?
The webcast replay will be available on Corvus' website for 90 days.
Corvus Pharmaceuticals Inc
CRVS Rankings
#678 Ranked by Stock Gains
CRVS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Burlingame
About CRVS
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.